Moderna’s COVID-19 vaccine has received full approval from the US Food and Drug Administration (FDA) for use in children with medical conditions that put them at higher risk of severe illness.

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.